Zebra Medical Vision’s AI solution for pleural effusion gains FDA clearance

Zebra Medical Vision has received FDA clearance for an AI solution designed to identify pleural effusion in chest x-rays.

The solution, HealthCXR, now joins Zebra Medical Vision’s growing AI1 bundle of AI-focused offerings for evaluating chest x-rays. This is the company’s fourth FDA clearance overall. Most recently, HealthPNX for detecting signs of pneumothorax was cleared in June.

“We are happy with the fourth FDA nod for an additional medical solution that will leverage AI in healthcare and improve patient care,” Eyal Gura, co-founder and CEO of Zebra Medical Vision, said in a prepared statement. “Adding a greater number of capabilities to our chest x-ray package is key for increasing doctors’ trust and the use of AI.”

“Based on the real-world application of this product, we saw that Zebra-Med's automatic identification of pleural effusion on chest x-rays can play a significant role in triage,” J.J. Visser, MD, PhD, a radiologist at Erasmus University Medical Center in the Netherlands, said in the same statement. “It could be a relevant indicator for acute cardiopulmonary disease, so that clinical management can be adopted, as soon as possible, in order to provide optimal patient care.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.